Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

Author: Benzinga Newsdesk | April 28, 2025 03:19am

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients
TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events
On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025
Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET

Posted In: TARA